Certin® Topcoat 201 TC201
A protective coating for new glass containers

Certin® Topcoat 201 being part of the CertinAdvance® coating line. The concept is built by 3 main parts, when combined ensures best coating properties without the use of the traditional spray bridge.

Certin® Topcoat 201 is applied on warm, single line positioned bottles, by use of the Certin® Precise application equipment. Depending on bottle shapes, the area(s) of application can be chosen to only apply where the final coating is required.

Advantages

By using Certin® Precise and Certin® Topcoat 201, following benefits are achieved:

- Avoiding potential of inside spraying
- Low temperature application possible, minimum ca 70°C
- Long-lasting protection of the glass surface
- Excellent dry scratch resistance
- Excellent wet scratch resistance
- Excellent protection during transportation
- Excellent wet smoothness after Pasteurisation processes

The basis for optimum performance of the Certin® TC201 a hot-end coating with a tin oxide layer of 35 CTU minimum.

- When applied on e.g. shoulder and heel, body label adhesions issues are prevented.
- In case of full body coating, self-adhesive labels are recommended.
- Very good wet scratch resistance during the filling process in zones where the glass containers accumulate and are exposed to pressure.
- In case of returnable containers, Certin® TC201 is fully compatible with Kercoat® 500.

Product & user data

Certin® Topcoat 201 is a weak-acidic stable wax dispersion

<table>
<thead>
<tr>
<th>Active ingredient</th>
<th>Wax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specific weight</td>
<td>1.0 g/cm³ (20°C)</td>
</tr>
<tr>
<td>Form</td>
<td>Dispersion</td>
</tr>
<tr>
<td>Colour</td>
<td>Yellow to orange</td>
</tr>
<tr>
<td>pH</td>
<td>approx. 4</td>
</tr>
</tbody>
</table>

Application conditions

Certin® Topcoat 201 normally is applied on fresh produced containers, having a hot-end coating layer of min 35 CTU, single line positioned and a temperature of minimum 70°C to max 125°C. Typical concentration is in the range of 0.5 up to 2.0%, chosen to only apply where the final coating is required.

Consumption

Consumption depends mainly on the amount and surface areas bottles to be coated.

Storage

Certin® Topcoat 201 must be stored in closed containers at room temperature (approx. 20°C).

Aqueous wax dispersions are generally susceptible to frost. Certin® Topcoat 201 should therefore be protected against frost during transport and storage.

If stored at proper warehouse conditions and in closed containers, the shelf life is 2 years after production date.

Product safety

On the basis of the Risk assessment done by TNO, using the Threshold Toxicological Concern Approach, which is supported by the World Health Organisation (WHO) and taking into account the real toxicological data available for several components of the above-mentioned product, Certin® Topcoat 201 is not expected to result in adverse health effects for consumers according to the foreseeable conditions of use.

Please refer to our health and safety data sheet for information on health and safety matters.
The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREFIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html). Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers’ medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use, performs or functions as intended, and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations.

Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.